Abstract: The aminoglycoside antibiotics, discovered as natural products in the 1940s, demonstrate a broad antimicrobial spectrum. Due to their nephrotoxic and ototoxic side effects, however, their widespread clinical usage has typically been limited to the treatment of serious infections. Neomycin B, first isolated from strains of Streptomyces in 1948, is one such drug that was approved for human use by the U.S. Food and Drug Administration in 1964. Only within the last 11 years has the biochemical pathway for its production been elaborated, however. Here we present the threedimensional architecture of NeoB from Streptomyces fradiae, which is a pyridoxal 5 0 -phosphate or PLP-dependent aminotransferase that functions on two different substrates in neomycin B biosynthesis. For this investigation, four high resolution X-ray structures of NeoB were determined in various complexed states. The overall fold of NeoB is that typically observed for members of the "aspartate aminotransferase" family with the exception of an additional three-stranded antiparallel b-sheet that forms part of the subunit-subunit interface of the dimer. The manner in which the active site of NeoB accommodates quite different substrates has been defined by this investigation. In addition, during the course of this study, we also determined the structure of the aminotransferase GenB1 to high resolution. GenB1 functions as an aminotransferase in gentamicin biosynthesis. Taken together, the structures of NeoB and GenB1, presented here, provide the first detailed descriptions of aminotransferases that specifically function on aldehyde moieties in aminoglycoside biosynthesis.
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Broader statement: Neomycin B, an aminoglycoside antibiotic isolated from Streptomyces fradiae, was first approved for human use by the U.S. Food and Drug Administration in 1964. The pathway for its biosynthesis requires 11 enzymes for 15 separate reactions. Here we describe the three-dimensional structure of NeoB, which catalyzes two of these reactions. The data presented provide new information that may prove useful in the development of novel antimicrobial therapeutics.
Introduction
Neomycin B is an aminoglycoside antibiotic that was first isolated in 1948 from the soil-dwelling bacterium Streptomyces fradiae.
1 Approved for human use by the U.S. Food and Drug Administration in 1964, it is thought to function by targeting the bacterial ribosome and inhibiting protein synthesis. 2 Whereas neomycin is most effective against Gramnegative bacteria, it does display some activity against Gram-positive organisms as well. 2 It is widely employed in the livestock industry for both disease prevention and increased efficiency of feed utilization. 3 For human use, neomycin is typically found in creams, ophthalmic suspensions, and ointments. 4 As indicated in Scheme 1, neomycin B is composed of four moieties: D-neosamine, 2-deoxystreptamine (2-DOS), D-ribose, and L-neosamine. 5 The biochemical pathway for its production requires 11 enzymes for 15 separate reactions. 6, 7 Two of the steps are catalyzed by NeoB as indicated in Scheme 2. 8 As isolated from S. fradiae, NeoB is composed of 416 amino acid residues and demonstrates amino acid sequence identities of less than 30% to any of the aminotransferases, whose structures have been deposited in the Protein Data Bank. All of our attempts to solve the three-dimensional structure of NeoB via molecular replacement failed. In addition, a selenomethionine-labeled version of NeoB that was subsequently prepared for MAD phasing yielded only poorly diffracting crystals. During the course of this investigation, however, we were able to solve the molecular structure of GenB1 from Micromonospora echinospora, which functions as an aminotransferase in the biosynthesis of gentamicin, an aminoglycoside antibiotic discovered in 1963. 9, 10 The reaction catalyzed by GenB1 is outlined in Scheme 3. 11, 12 Importantly, GenB1 shows amino acid sequence similarities and identities of 70% and 56%, respectively, to NeoB, which allowed us to finally obtain a three-dimensional model of NeoB via molecular replacement. Herein we report the high-resolution X-ray structures of NeoB and GenB1. Taken together, the models provide new details into those aminotransferases involved in the biosynthesis of aminoglycoside antibiotics.
Results and Discussion
Overall structure of NeoB from S. fradiae NeoB belongs to the aspartate aminotransferase superfamily of enzymes that utilize PLP as their cofactors. 13 With one notable exception thus far, namely ColD from Escherichia coli, 14 most contain an active site lysine residue that forms a Schiff base with the cofactor as shown in Scheme 4. This is referred to as the internal aldimine. 15 On the basis of amino acid sequence alignments, it was expected that Lys 231 in NeoB would form the Schiff base with the cofactor. In an attempt to determine the structure of NeoB in its internal aldimine form, E. coli cells harboring the appropriate plasmid (Materials and Methods section) were grown in lysogeny broth. Surprisingly, the isolated protein displayed a distinctly pink color, and the crystals utilized in the structural analysis (two dimers in asymmetric unit) were also pink. This first model of NeoB was refined to 1.75 Å resolution with an overall R-factor of 17.6%. The four subunits in the asymmetric unit superimpose with a root-mean-square deviation of 0.2 Å . Shown in Figure 1 (A) is the observed electron density for the cofactor in subunit 3. Notably there is no bond between Lys 231 and the cofactor. Rather pyridoxamine 5 0 -phosphate, or PMP, is trapped in the active site. Indeed, this "pink" form of an aminotransferase was first observed in 1994 for glutamate 1-semialdehyde aminotransferase 17 and was subsequently shown to be caused by the presence of PMP. 18 As noted in the Materials and Methods section, when the E. coli cells harboring plasmids encoding the NeoB gene were grown in M9 minimal media, the resulting protein was yellow as expected for a PLP-containing enzyme. Our results provide yet another cautionary tale about the utilization of lysogeny broth for some experiments. Indeed, it has been shown that steady-state cellular growth in lysogeny broth ends at an optical density of 0.3 at 600 nm. 19 Afterwards, the physiological states of the bacterial cells are constantly changing, which could present Scheme 1. The molecular structure of neomycin B.
issues depending upon the specific experiments being conducted. Shown in Figure 1 (B) is a ribbon representation of the NeoB dimer. The subunit-subunit interface is extensive with a total buried surface area is 6800 A search with the online SSM server 21 reveals that the overall architecture of NeoB is most closely similar to that observed for the glutamate-1-semialdehyde 2,1-aminomutases. 21 Like NeoB, these enzymes contain the three-stranded antiparallel b-sheet insertion.
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A close-up stereo view of the NeoB active site with bound PMP is presented in Figure 2 . Both subunits contribute to the cofactor binding pocket. The phosphoryl moiety of the PMP ligand forms Amino-containing substrates, such as neamine, can displace the lysine side chain to form an external aldimine via a transimination reaction (Scheme 4). The next structure determined in this investigation was that of NeoB in complex with neamine, which provided a detailed description of the external aldimine form. The model was refined to 1.6 Å resolution with an overall R-factor of 19.9%. The electron densities for the eight polypeptide chain backbones in the asymmetric unit were continuous from Ser 6 to Leu 414 (the last two aspartate residues at the C-terminus were disordered in the map). The root-mean-square deviations between the a-carbons of the eight subunits range from 0.1 to 0.3 Å . Given the close structural correspondence between the eight subunits, only the first dimer in the asymmetric unit will be described here.
The observed electron density corresponding to the external aldimine in subunit 1 is shown in Figure  3 (A). Whereas the electron densities for the cofactor and the D-neosamine moiety are well ordered, that for the 2-DOS group is somewhat weaker. The D-neosamine adopts the 4 C 1 conformation. A close-up view of the active site is provided in Figure 3 (B). Like that observed for the NeoB/PMP complex, the phosphoryl group of the PLP is tightly anchored into the active site via numerous hydrogen bonds and three water molecules. The D-neosamine is positioned into the active site by the side chains of Lys 207, Lys 231, and Asp 344. In addition, the carbonyl oxygen of Val 392 lies within 3.1 Å of the C-2 amino group. In contrast, there are fewer protein interactions with the 2-DOS group. Indeed, only the side chain of Asp 394 lies within 3.2 Å of it. As is often observed in proteinsugar interactions, an aromatic side chain (Tyr 129) abuts one side the 2-DOS group.
NeoB functions on two different substrates (Scheme 2). In attempt to understand the manner by which NeoB accommodates neomycin in the external aldimine form, the third structure determined in this investigation was that of the protein in complex with the antibiotic. The crystals were obtained at pH 9.0 (one dimer in the asymmetric unit), and the structure was determined and refined to 1.65 Å resolution with an overall R-factor of 16.3%. The a-carbons for the two subunits of the dimer superimpose with a root-mean-square deviation of 0.2 Å . Shown in Figure 4 (A) is the observed electron density corresponding to the external aldimine in subunit 1 of the dimer. The electron densities for Rings 4 (D-neosamine), 3 (D-ribose), and 1 (2-DOS) are well ordered whereas that for Ring 2 (Dneosamine) is weaker. Note that the neomycin utilized in the crystallizations was a mixture of neomycin B (a minimum of 85%), neomycin C, and other contaminants (Sigma-Aldrich). Neomycin B and C differ in stereochemistry about their C-5 000 carbons (Schemes 1 and 2). As is clearly visible in Figure  4 (A), NeoB displays strict substrate specificity about the C-5 000 carbon such that it only formed the external aldimine with neomycin C, although the majority of the neomycin mixture was neomycin B.
A close-up view of the active site with the bound external aldimine is presented in Figure 4 A comparison of the external aldimines formed between PLP and either neamine or neomycin C is shown in Figure 5 . There are no significant changes in the orientations of the side chains surrounding the external aldimines. With respect to the ligands, the 2-DOS moiety of neamine (Ring 1) binds in the same general position as that observed for the Dribose of neomycin (Ring 3).
The original crystals of the external aldimine with neomycin C were obtained at pH 9.0, and thus there is always concern regarding artifactual Scheme 4. Structures of the internal and external aldimine forms of PLP. Figure 1 . Structure of NeoB. Shown in stereo in (A) is the electron density observed for the PMP moiety. The map, contoured at 3r, was calculated with coefficients of the form F o -F c , where F o was the native structure factor amplitude and F c was the calculated structure factor amplitude. Note that the ligands were not included in the coordinate file used to calculate the initial map. A ribbon representation of the NeoB dimer is displayed in (B) with the b-strands of subunits 1 and 2 highlighted in violet and blue, respectively, and the a-helices colored in light blue and wheat, respectively. The three-stranded antiparallel b-sheet insertions are highlighted in orange and green, in subunits 1 and 2, respectively. A stereo view of subunit 1 is provided in (C). All figures were prepared using PyMOL.
binding. To ensure that this was not the case, a subsequent crystal form of the NeoB/neomycin external aldimine complex was grown at pH 7.5. The crystals diffracted to 1.35 Å resolution, and the model was refined to an overall R-factor of 17.3%. Importantly, the two structures, determined at pH 9.0 and 7.5, are virtually identical such that all their atoms superimpose with a root-mean-square deviation of 0.1 Å .
Overall structure of GenB1 from M. echinospora
The structure of GenB1 determined in this investigation was that in complex with neamine, a smaller analog than its natural substrate which contains an additional hexose moiety (Scheme 3). The model was refined to 1.6 Å resolution with an overall R-factor of 15.7%. The a-carbons for the four subunits in the asymmetric unit superimpose with root-mean-square deviations of between 0.1 and 0.3 Å . Not surprisingly, its overall molecular architecture is nearly Figure 4 . The NeoB external aldimine with neomycin C. The observed electron density for the external aldimine is presented in stereo in (A). The omit map was calculated as described in figure legend 1 and contoured at 3r. Possible hydrogen bonding interactions between the cofactor and the protein, as indicated by the dashed lines, are displayed in stereo in (B). Those amino acid residues belonging to subunit 2 are labeled with asterisks. Figure 5 . Comparison of the NeoB external aldimines with either neamine or neomycin C. In this stereo drawing, the structure of the NeoB/external aldimine with neamine is highlighted in light blue bonds, whereas that of the enzyme with neomycin C is colored in violet bonds. Those amino acid residues belonging to subunit 2 are labeled with asterisks.
identical to that described for NeoB. Indeed, the acarbons for the GenB1 and NeoB models superimpose with a root-mean-square deviation of 0.7 Å . Figure 6 (A) is the observed electron density for the external aldimine in subunit 3. Again, as observed with NeoB, the electron density for the D- Figure 6 . The external aldimine in GenB1. Shown in stereo in (A) is the observed electron density for the external aldimine. The omit map was calculated as described in figure legend 1 and contoured at 3r. A close-up stereo view of the GenB1 active site is presented in (B). GenB1 and NeoB accommodate the cofactor and the D-neamine moieties in nearly identical manners as can be seen in (C). The 2-DOS groups, however, are rotated by nearly 1808 with respect to one another. The NeoB external aldimine is shown in blue whereas that for GenB1 is depicted in gray.
Shown in
neosamine moiety is well ordered, whereas that for the 2-DOS group is somewhat weaker most likely due to fewer protein-ligand interactions. A close-up stereo view of the region surrounding the GenB1 external aldimine is presented in Figure 6 (B). There is a remarkable conservation in the manner by which the external aldimines in NeoB and GenB1 are anchored into the active site clefts with respect to the D-neosamine groups. The only significant difference is the hydrogen bond between Thr 16 and a hydroxyl group of the 2-DOS moiety in GenB1. This hydrogen bond does not occur in NeoB because the 2-DOS moiety is positioned in the active site quite differently. Strikingly, the 2-DOS moieties in NeoB and GenB1 are rotated by nearly 1808 with respect to one another [ Fig. 6(C) ]. Given that neamine is not the true substrate for GenB1, there is the caveat that the different positioning of the 2-DOS groups in these proteins is an artifact.
In conclusion, since their discovery in 1940s, the aminoglycoside antibiotics remain, despite toxicity problems, important therapeutics for serious Gramnegative infections. 23 Only within the last 20 years, however, have the pathways for their production been unraveled via both bioinformatics and biochemical approaches. Here we demonstrate for the first time the manner in which two aminotransferases involved in their production, namely NeoB and GenB1, accommodate their respective substrate or substrate analog. Given the alarming rise of antibiotic resistance, it is not surprising that researchers are once again exploring the possible development of novel aminoglycosides. Indeed, 19 patents alone were filed between 2011 and 2015 in an effort to produce unique aminoglycosidebased antimicrobials that are bacterial resistant and that display decreased nephrotoxic and ototoxic properties. 24 The data presented here may provide researchers strategies for the development of new aminoglycoside scaffolds.
Materials and Methods

Cloning, expression, and purification
The gene encoding GenB1 was cloned from M. echinospora (ATCC 15835) genomic DNA using Platinum Pfx DNA polymerase (Invitrogen). Primers were designed that incorporated NdeI and XhoI 
where F o is the observed structure-factor amplitude and F c. is the calculated structure-factor amplitude. d Distribution of Ramachandran angles according to PROCHECK. 34 restriction sites. The PCR product was digested with NdeI and XhoI and ligated into pET28T3G, a laboratory pET28b(1) vector that had been previously modified to incorporate a TEV protease cleavage recognition site after the N-terminal polyhistidine tag. 25 The pET28T3G-genB1 plasmid was utilized to transform Rosetta2(DE3) E. coli cells (Novagen). The cultures were grown in lysogeny broth supplemented with kanamycin (50 mg/L) and chloramphenicol (50 mg/L) at 378C with shaking until an optical density of 0.8 was reached at 600 nm. The flasks were cooled in an ice bath, and protein expression was initiated with the addition of 1 mM isopropyl b-D-1-thiogalactopyranoside. The cells were then allowed to grow at 228C for 18 h.
The cells were harvested by centrifugation and disrupted by sonication on ice. The lysate was cleared by centrifugation, and GenB1 was purified with Prometheus TM Ni-NTA agarose (Prometheus Protein Biology Products) according to the manufacturer's instructions. The polyhistidine tag was removed by digestion with TEV protease. The TEV protease and remaining tagged GenB1 were removed by passage over Ni-NTA agarose, and the tag-free protein was dialyzed against 10 mM Tris-HCl (pH 8.0) and 200 mM NaCl and concentrated to 22 mg/mL based on an extinction coefficient of 0.72 (mg/mL) 21 cm
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. Selenomethionine-labeled protein was expressed using standard methods 26 and purified in the same manner as that described for the wild-type enzyme. The gene encoding NeoB was cloned from S. fradiae (ATCC 10745) genomic DNA in a similar manner to that described for GenB1. It was ligated into pET28T3G (as above) and also into pET31b(1) to give a protein construct with a noncleavable Cterminal six-histidine tag.
The pET28T3G-neoB and pET31-neoB plasmids were utilized to transform Rosetta2(DE3) E. coli cells (Novagen). The cultures were grown in lysogeny broth supplemented with kanamycin (50 mg/L) and chloramphenicol (50 mg/L) or ampicillin (100 mg/L) and chloramphenicol (50 mg/L), respectively, at 378C with shaking until an optical density of 0.8 was reached at 600 nm. The flasks were cooled in an ice bath, and protein expression was initiated with the addition of 1 mM isopropyl b-D-1-thiogalactopyranoside. The cells were then allowed to grow at 228C for 18 h. The cells were harvested by centrifugation and disrupted by sonication on ice. The lysate was cleared by centrifugation, and NeoB was purified using Ni-NTA agarose. The purified pool of protein with the N-terminal histidine tag was split in half, one portion kept to retain the tag and the other digested with TEV protease to remove it. All resulting pools of protein (N-terminal histidine tag, "cleaved", and C-terminal histidine tag) were dialyzed against 10 mM Tris-HCl (pH 8.0) and 200 mM NaCl and concentrated to 20 mg/mL based on an extinction coefficient of 0.85 mg/mL 21 cm
. Surprisingly, all of the NeoB proteins isolated from growths in lysogeny broth displayed an intense pink color.
Cultures were subsequently grown in M9 minimal media under conditions analogous to that employed for growth in lysogeny broth. Identical purification protocols were followed, but this time the protein solutions were yellow in color as would be expected for PLPcontaining enzymes.
Crystallization and structural analysis
Crystallization conditions for GenB1 were surveyed at both room temperature and 48C by the hanging drop method of vapor diffusion using a laboratory based sparse matrix screen. X-ray diffraction quality crystals of the enzyme were subsequently grown from precipitant solutions containing 17 to 19% poly(ethylene glycol) 8000, 1 mM PLP, 5 mM neamine (Scheme 2), 2% 2-propanol, and 100 mM MES (pH 6.0) at 218C. The crystals belonged to the space group P2 1 with unit cell dimensions of a 5 66.9 Å , b 5 60.0 Å , c 5 210.7 Å , and b 5 95.28. The asymmetric unit contained two dimers.
For X-ray data collection, the crystals were transferred to a cryoprotectant solution containing 22% poly(ethylene glycol) 8000, 300 mM NaCl, 1 mM PLP, 15% ethylene glycol, 5 mM neamine, and 100 mM MES (pH 6.0). The X-ray data were collected at the Advanced Photon Source, Structural Biology Center Beamline 19-BM. These X-ray data were processed with HKL3000. 27 Crystals of the selenomethionine-labeled protein were grown under identical conditions to those for the wild-type protein, and they belonged to the same space group. The crystals were cryo-protected in a similar manner to that discussed above. X-ray data were collected at the Advanced Photon Source (peak wavelength 0.9794 Å ) and processed with HKL3000. The structure of GenB1 was determined via single anomalous dispersion (SAD) phasing with the software packages SOLVE and RESOLVE. 28, 29 Iterative cycles of model building with COOT and refinement with REFMAC against the X-ray data collected from crystals of the wild-type protein reduced the R work and R free to 15.5% and 18.8%, respectively, from 50 to 1.6 Å resolution.
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The "pink" NeoB proteins were screened for crystallization properties in the absence of additional ligands. Crystals ultimately used for X-ray data collection were grown at 218C with protein containing the noncleavable C-terminal histidine tag. Specifically, they were obtained from 14 to 18% poly(ethylene glycol) 8000, 200 mM tetraethylammonium chloride, and 100 mM HEPES (pH 7.5). They belonged to the triclinic space group P1 (2 dimers in the asymmetric unit) with unit cell dimensions of
For X-ray data collection, the crystals were transferred to a solution composed of 24% poly(ethylene glycol) 8000, 300 mM NaCl, 300 mM tetraethylammonium chloride, 15% ethylene glycol, and 100 mM HEPES (pH 7.5). The X-ray data were collected at the Advanced Photon Source and were processed with HKL3000. 27 The "pink" NeoB structure was solved via molecular replacement with PHASER using the GenB1 coordinates as a search model. 33 Iterative cycles of model building with COOT and refinement with REFMAC reduced the R work and R free to 17.5% and 20.7%, respectively, from 50 to 1.75 Å resolution. [30] [31] [32] The "yellow" NeoB proteins were initially screened for crystallization properties in the presence of 5 mM neamine (Scheme 2) and 1 mM PLP. X-ray diffraction quality crystals were obtained with the protein containing the noncleavable C-terminal histidine tag. Specifically, the crystals were grown from 16 to 21% poly(ethylene glycol) 3350, 300 mM KCl, and 100 mM HEPES (pH 7.5) at 218C. These crystals belonged to the space group P2 1 with unit cell dimensions of a 5 70.4 Å , b 5 107.4 Å , c 5 217.5 Å , b 5 98.28, and four dimers in the asymmetric unit.
They were prepared for X-ray data collection by transferring them to a cryo-protectant solution composed of 28% poly(ethylene glycol) 8000, 300 mM NaCl, 300 mM KCl, 15% ethylene glycol, 1 mM PLP, 5 mM neamine (Scheme 2), and 100 mM HEPES (pH 7.5). The X-ray data were collected at the Advanced Photon Source and were processed with HKL3000. 27 The "yellow" NeoB structure was solved by molecular replacement with PHASER using as a search model the coordinates for the "pink" NeoB protein. Iterative cycles of model building with COOT and refinement with REFMAC reduced the R work and R free to 19.6% and 24.3%, respectively, from 50 to 1.6 Å resolution. [30] [31] [32] Subsequent crystal screens with the "yellow" NeoB protein were performed in the presence of 1 mM PLP and 5 mM neomycin (Scheme 2). One crystal form was grown from 18 to 20% poly(ethylene glycol) 3350, 100 mM MgCl 2 , and 100 mM CHES (pH 9.0) using protein that retained the Nterminal tag. The crystals belonged to the triclinic space group P1 (one dimer in the symmetric unit) with unit cell dimensions of a 5 57.7 Å , b 5 59.2 Å , c 5 70.3 Å , a 5 69.68, b 5 77.68, and c 5 78.58. They were prepared for X-ray data collection by transferring them to a solution composed of 25% poly(ethylene glycol) 3350, 300 mM NaCl, 100 mM MgCl 2 , 1 mM PLP, 5 mM neomycin (Scheme 2), 15% ethylene glycol, and 100 mM CHES (pH 9.0). The X-ray data from these crystals were collected in-house with a Bruker AXS Platinum-135 CCD detector controlled with the PROTEUM software package (Bruker AXS). The X-ray source was Cu Ka radiation from a Rigaku RU200 X-ray generator equipped with Montel optics. The X-ray data were processed with SAINT and scaled with SADABS (Bruker AXS). The structure was solved by molecular replacement with PHASER using as a search model the coordinates of NeoB in complex with the neamine external aldimine. Iterative cycles of model building with COOT and refinement with REFMAC reduced the R work and R free to 16.1% and 19.8%, respectively, from 50 to 1.65 Å resolution. [30] [31] [32] A second crystal form of the "yellow" protein was obtained at pH 7.5 using protein which had the N-terminal histidine tag removed. These crystals were grown from 18 to 20% poly(ethylene glycol) 5000, 200 mM LiCl, and 100 mM HEPES (pH 7.5) and belonged to the space group P2 1 with unit cell dimensions of a 5 59.3 Å , b 5 109.6 Å , c 5 70.4 Å , and b 5 110.58 and one dimer in the asymmetric unit. They were prepared for X-ray data collection by transferring them to a solution composed of 25% poly(ethylene glycol) 5000, 300 mM NaCl, 200 mM LiCl, 1 mM PLP, 5 mM neomycin, 18% ethylene glycol, and 100 mM HEPES (pH 7.5). The X-ray data were collected in-house as described above. The structure was solved by molecular replacement with PHASER using the NeoB coordinates, determined at pH 9.0, as a search model. Iterative cycles of model building with COOT and refinement with REFMAC reduced the R work and R free to 17.2% and 19.7%, respectively, from 50 to 1.35 Å resolution. [30] [31] [32] All relevant X-ray data collection and model refinement statistics are presented in Table I . The accession codes for GenB1 and NeoB are GenBank AAR98542.1 and BAD95831.1, respectively.
